Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

United Biopharma of Taiwan to Build $40 Million mAb Manufacturing Facility in China

publication date: Mar 14, 2018

United Biopharma, a Taiwan based pharmaceutical company, will build a mAb manufacturing facility in Yangzhou, China to supply the China market with its novel and biosimilar candidates. To finance the facility, UBP Yangzhou signed a $40 million loan agreement with Yangzhou High Technology Industry Park. Using these funds, UBP Yangzhou will partner with GE Healthcare Life Sciences to supply the facility with six single-use bioreactors (2x200L, 3x500L and 2x2000L). This facility is expected to test run in June 2019. In Taiwan, UBP will work with GE Healthcare to establish a contract development and manufacturing (CDMO) service. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital